The clinical efficacy and safety of certolizumab pegol (CZP) in the treatment of rheumatoid arthritis: focus on long-term use, patient considerations and the impact on quality of life

Roy FleischmannMetroplex Clinical Research Center, Dallas, Texas, USAAbstract: Rheumatoid arthritis can cause chronic pain, disability, fatigue and loss of productivity both in the workplace and at home. Fatigue, not joint pain, swelling or that there may be radiographic damage, is frequently mentio...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Roy Fleischmann
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	Diseases of the musculoskeletal system RC925-935
Acceso en línea:	https://doaj.org/article/3615454d2ee6495c8f86318a2856b336
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3615454d2ee6495c8f86318a2856b336
record_format	dspace
spelling	oai:doaj.org-article:3615454d2ee6495c8f86318a2856b3362021-12-02T05:57:51ZThe clinical efficacy and safety of certolizumab pegol (CZP) in the treatment of rheumatoid arthritis: focus on long-term use, patient considerations and the impact on quality of life1179-156Xhttps://doaj.org/article/3615454d2ee6495c8f86318a2856b3362009-07-01T00:00:00Zhttp://www.dovepress.com/the-clinical-efficacy-and-safety-of-certolizumab-pegol-czp-in-the-trea-a3356https://doaj.org/toc/1179-156XRoy FleischmannMetroplex Clinical Research Center, Dallas, Texas, USAAbstract: Rheumatoid arthritis can cause chronic pain, disability, fatigue and loss of productivity both in the workplace and at home. Fatigue, not joint pain, swelling or that there may be radiographic damage, is frequently mentioned by patients as their most debilitating problem. In the era prior to biologic therapy in rheumatoid arthritis, it was reported that 40% to 50% of individuals reported work loss within 10 years of the onset of their disease. Rheumatoid arthritis is not just associated with chronic pain and inability to function normally; there is a significant economic burden caused by the disease which affects society as well the individual. Work disability in individuals with rheumatoid arthritis occurs early and increases over time. Early, aggressive treatment has now become the norm in clinical practice with changes of medication dictated by measuring the presence of continued disease activity. The combination of adequately dosed methotrexate and a biologic agent, especially a TNF&alpha; inhibitor, has been shown to be far more effective than traditional disease modifying anti-rheumatic drugs in early and long-standing disease, with respect to clinical, radiologic and functional outcomes. Unfortunately, not all patients respond to all medications equally; indeed a patient may fail a number of medications, either alone or in combination, and then respond to another medication. For this reason, there is room in our therapeutic armamentarium for additional effective agents such as certolizumab pegol. The results of up to 100 weeks of treatment with certolizumab pegol with an emphasis on functional outcomes, is the focus of this review.Keywords: certolizumab, rheumatoid arthritis, anti-TNF therapy; efficacy, safety, quality of life Roy FleischmannDove Medical PressarticleDiseases of the musculoskeletal systemRC925-935ENOpen Access Rheumatology: Research and Reviews, Vol 2009, Iss default, Pp 95-106 (2009)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the musculoskeletal system RC925-935
spellingShingle	Diseases of the musculoskeletal system RC925-935 Roy Fleischmann The clinical efficacy and safety of certolizumab pegol (CZP) in the treatment of rheumatoid arthritis: focus on long-term use, patient considerations and the impact on quality of life
description	Roy FleischmannMetroplex Clinical Research Center, Dallas, Texas, USAAbstract: Rheumatoid arthritis can cause chronic pain, disability, fatigue and loss of productivity both in the workplace and at home. Fatigue, not joint pain, swelling or that there may be radiographic damage, is frequently mentioned by patients as their most debilitating problem. In the era prior to biologic therapy in rheumatoid arthritis, it was reported that 40% to 50% of individuals reported work loss within 10 years of the onset of their disease. Rheumatoid arthritis is not just associated with chronic pain and inability to function normally; there is a significant economic burden caused by the disease which affects society as well the individual. Work disability in individuals with rheumatoid arthritis occurs early and increases over time. Early, aggressive treatment has now become the norm in clinical practice with changes of medication dictated by measuring the presence of continued disease activity. The combination of adequately dosed methotrexate and a biologic agent, especially a TNF&alpha; inhibitor, has been shown to be far more effective than traditional disease modifying anti-rheumatic drugs in early and long-standing disease, with respect to clinical, radiologic and functional outcomes. Unfortunately, not all patients respond to all medications equally; indeed a patient may fail a number of medications, either alone or in combination, and then respond to another medication. For this reason, there is room in our therapeutic armamentarium for additional effective agents such as certolizumab pegol. The results of up to 100 weeks of treatment with certolizumab pegol with an emphasis on functional outcomes, is the focus of this review.Keywords: certolizumab, rheumatoid arthritis, anti-TNF therapy; efficacy, safety, quality of life
format	article
author	Roy Fleischmann
author_facet	Roy Fleischmann
author_sort	Roy Fleischmann
title	The clinical efficacy and safety of certolizumab pegol (CZP) in the treatment of rheumatoid arthritis: focus on long-term use, patient considerations and the impact on quality of life
title_short	The clinical efficacy and safety of certolizumab pegol (CZP) in the treatment of rheumatoid arthritis: focus on long-term use, patient considerations and the impact on quality of life
title_full	The clinical efficacy and safety of certolizumab pegol (CZP) in the treatment of rheumatoid arthritis: focus on long-term use, patient considerations and the impact on quality of life
title_fullStr	The clinical efficacy and safety of certolizumab pegol (CZP) in the treatment of rheumatoid arthritis: focus on long-term use, patient considerations and the impact on quality of life
title_full_unstemmed	The clinical efficacy and safety of certolizumab pegol (CZP) in the treatment of rheumatoid arthritis: focus on long-term use, patient considerations and the impact on quality of life
title_sort	clinical efficacy and safety of certolizumab pegol (czp) in the treatment of rheumatoid arthritis: focus on long-term use, patient considerations and the impact on quality of life
publisher	Dove Medical Press
publishDate	2009
url	https://doaj.org/article/3615454d2ee6495c8f86318a2856b336
work_keys_str_mv	AT royfleischmann theclinicalefficacyandsafetyofcertolizumabpegolczpinthetreatmentofrheumatoidarthritisfocusonlongtermusepatientconsiderationsandtheimpactonqualityoflife AT royfleischmann clinicalefficacyandsafetyofcertolizumabpegolczpinthetreatmentofrheumatoidarthritisfocusonlongtermusepatientconsiderationsandtheimpactonqualityoflife
_version_	1718400102332104704

The clinical efficacy and safety of certolizumab pegol (CZP) in the treatment of rheumatoid arthritis: focus on long-term use, patient considerations and the impact on quality of life

Ejemplares similares